| Next 10 |
Ad
TLSA News and Press Tiziana Life Sciences plc
News | Tiziana Life Sciences plc (NASDAQ:TLSA)
-
2025-05-20 10:49:50 ET More on Tesla, Home Depot, etc. Tesla's Future: Robotaxi Dreams Meet Overbought Signals Tesla: An Energy Giant In The Making Tesla's Hot Streak Faces Reality Check: Can The Rally Hold? Elon Musk sees still being CEO of Tesla in five yea...
-
2025-05-12 08:04:49 ET More on Tiziana Life Sciences Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment Tiziana posts favorable PET scan data for lead asset in Alzheimer's Tiziana rises on positive results in multiple sclerosis treatment st...
-
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human a...
-
2025-05-09 07:33:51 ET More on Tiziana Life Sciences Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment Tiziana rises on positive results in multiple sclerosis treatment study Tiziana Life Sciences ticks up on IND submission for mid-stage t...
-
2025-05-06 09:08:33 ET More on Tiziana Life Sciences Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment Tiziana stock jumps 12% on TBI drug study publ...
-
2025-04-01 16:15:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ. After dropping to a l...
-
2025-03-24 17:36:24 ET Tiziana Life Sciences ( NASDAQ: TLSA ) filed for $250M mixed securities shelf. This prospectus is not an offer to sell. Filing Read the full article on Seeking Alpha For further details see: Tiziana Life Sciences files for ...
-
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...
-
2025-03-14 08:37:48 ET More on Tiziana Life Sciences Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment Tiziana stock jumps 12% on TBI drug study publ...
-
2025-03-05 17:52:20 ET Summary The company is evaluating the use of fully human intranasal anti-CD3 monoclonal antibody foralumab for the treatment of patients with Secondary Progressive Multiple Sclerosis in a phase 2a study. The global multiple sclerosis drugs market size is pro...
Stock Information
Get TLSA Alerts
News, Short Squeeze, Breakout and More Instantly...
Tiziana Life Sciences plc Company Name:
TLSA Stock Symbol:
NASDAQ Market:
-6.0% G/L:
$1.41 Last:
192,752 Volume:
$1.49 Open:
$1.50 Close:
Tiziana Life Sciences plc Website:
Ad
-
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human a...
-
2025-04-01 16:15:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ. After dropping to a l...
-
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...